BioNxt Expands Capabilities with New Munich Lab Integration

BioNxt Solutions Inc., a bioscience company dedicated to advanced drug delivery systems, has announced a strategic move to centralize its research, development, and commercialization efforts in Munich, Germany. This integration with Gen-Plus GmbH & Co. KG enhances BioNxt's capacity for innovation through access to state-of-the-art laboratory facilities and collaboration opportunities within a prominent European biotech hub.

The 1,000-square-meter Gen-Plus laboratory is equipped to handle high-potency pharmaceutical ingredients and compliant production processes. BioNxt aims to leverage this cutting-edge infrastructure, particularly focusing on its development of neurodegenerative therapeutics and proprietary drug delivery systems.

An immediate priority for BioNxt and Gen-Plus is the development of BNT23001, a sublingual thin-film formulation of Cladribine intended for multiple sclerosis treatment. Preparations for a human bioequivalence study are underway, including product transfer, manufacturing upscaling, and analytical validation.